Businesses and individuals that have money deposited with failed US bank Silicon Valley Bank (SVB) will be able to access all their cash from today, said the US government.
BeiGene has announced approval from the China National Medical Products Administration (NMPA) to begin manufacturing its anti-PD-1 antibody, tislelizumab, at its biologics facility in Guangzhou, China.
BeiGene’s immunotherapy becomes its first treatment to receive approval in China and Boehringer announces that it has begun manufacture of the product.
This month’s round-up of the most popular stories of the month, featuring a bold prediction of future growth for Chinese biotech and bad news for a potential treatment for Alzheimer’s disease.
